Logo image of SALME.OL

SALMON EVOLUTION ASA (SALME.OL) Stock Fundamental Analysis

OSL:SALME - Euronext Oslo - NO0010892094 - Common Stock - Currency: NOK

6  -0.03 (-0.5%)

Fundamental Rating

3

Overall SALME gets a fundamental rating of 3 out of 10. We evaluated SALME against 57 industry peers in the Food Products industry. SALME scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SALME shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SALME has reported negative net income.
In the past year SALME had a positive cash flow from operations.
In the past 5 years SALME always reported negative net income.
SALME had negative operating cash flow in 4 of the past 5 years.
SALME.OL Yearly Net Income VS EBIT VS OCF VS FCFSALME.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M

1.2 Ratios

SALME's Return On Assets of -1.49% is on the low side compared to the rest of the industry. SALME is outperformed by 78.95% of its industry peers.
With a Return On Equity value of -2.13%, SALME is not doing good in the industry: 77.19% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -1.49%
ROE -2.13%
ROIC N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
SALME.OL Yearly ROA, ROE, ROICSALME.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

With an excellent Gross Margin value of 63.37%, SALME belongs to the best of the industry, outperforming 92.98% of the companies in the same industry.
SALME's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SALME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
SALME.OL Yearly Profit, Operating, Gross MarginsSALME.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

SALME does not have a ROIC to compare to the WACC, probably because it is not profitable.
SALME has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SALME has been increased compared to 5 years ago.
Compared to 1 year ago, SALME has an improved debt to assets ratio.
SALME.OL Yearly Shares OutstandingSALME.OL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
SALME.OL Yearly Total Debt VS Total AssetsSALME.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

SALME has an Altman-Z score of 1.93. This is not the best score and indicates that SALME is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of SALME (1.93) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.26 indicates that SALME is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.26, SALME belongs to the top of the industry, outperforming 82.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 1.93
ROIC/WACCN/A
WACC8.01%
SALME.OL Yearly LT Debt VS Equity VS FCFSALME.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

SALME has a Current Ratio of 2.03. This indicates that SALME is financially healthy and has no problem in meeting its short term obligations.
SALME has a Current ratio of 2.03. This is in the better half of the industry: SALME outperforms 75.44% of its industry peers.
A Quick Ratio of 1.54 indicates that SALME should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.54, SALME is doing good in the industry, outperforming 78.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 1.54
SALME.OL Yearly Current Assets VS Current LiabilitesSALME.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.27% over the past year.
The Revenue has grown by 205.25% in the past year. This is a very strong growth!
The Revenue has been growing by 238.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)70.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)205.25%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%67.35%

3.2 Future

SALME is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.27% yearly.
The Revenue is expected to grow by 62.10% on average over the next years. This is a very strong growth
EPS Next Y109.36%
EPS Next 2Y74.45%
EPS Next 3Y92.99%
EPS Next 5Y103.27%
Revenue Next Year15.78%
Revenue Next 2Y30.97%
Revenue Next 3Y51.3%
Revenue Next 5Y62.1%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SALME.OL Yearly Revenue VS EstimatesSALME.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B 5B
SALME.OL Yearly EPS VS EstimatesSALME.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SALME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 582.52, SALME can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SALME indicates a slightly more expensive valuation: SALME is more expensive than 77.19% of the companies listed in the same industry.
SALME is valuated expensively when we compare the Price/Forward Earnings ratio to 20.42, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 582.52
SALME.OL Price Earnings VS Forward Price EarningsSALME.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400

4.2 Price Multiples

SALME's Enterprise Value to EBITDA ratio is rather expensive when compared to the industry. SALME is more expensive than 87.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 43.38
SALME.OL Per share dataSALME.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SALME does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as SALME's earnings are expected to grow with 92.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y74.45%
EPS Next 3Y92.99%

More info and screens

0

5. Dividend

5.1 Amount

SALME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SALMON EVOLUTION ASA

OSL:SALME (5/6/2025, 7:00:00 PM)

6

-0.03 (-0.5%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-11 2025-02-11/bmo
Earnings (Next)05-13 2025-05-13
Inst Owners22.26%
Inst Owner ChangeN/A
Ins Owners1.08%
Ins Owner ChangeN/A
Market Cap2.78B
Analysts85
Price Target9.63 (60.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-629.5%
Min EPS beat(2)-1265.05%
Max EPS beat(2)6.04%
EPS beat(4)2
Avg EPS beat(4)-311.86%
Min EPS beat(4)-1265.05%
Max EPS beat(4)100%
EPS beat(8)3
Avg EPS beat(8)-184.15%
EPS beat(12)7
Avg EPS beat(12)-108.13%
EPS beat(16)10
Avg EPS beat(16)-83.74%
Revenue beat(2)1
Avg Revenue beat(2)-15.95%
Min Revenue beat(2)-33.87%
Max Revenue beat(2)1.98%
Revenue beat(4)2
Avg Revenue beat(4)-9.66%
Min Revenue beat(4)-33.87%
Max Revenue beat(4)4.66%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.5%
PT rev (3m)-2.94%
EPS NQ rev (1m)-99.94%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-80.56%
EPS NY rev (3m)-58.83%
Revenue NQ rev (1m)-15.13%
Revenue NQ rev (3m)-25.22%
Revenue NY rev (1m)-4.61%
Revenue NY rev (3m)-5.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 582.52
P/S 5.93
P/FCF N/A
P/OCF 64.06
P/B 1.25
P/tB 1.3
EV/EBITDA 43.38
EPS(TTM)-0.11
EYN/A
EPS(NY)0.01
Fwd EY0.17%
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)0.09
OCFY1.56%
SpS1.01
BVpS4.81
TBVpS4.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.49%
ROE -2.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.37%
FCFM N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
F-Score5
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA 8.1
Cap/Depr 486.93%
Cap/Sales 79.27%
Interest Coverage N/A
Cash Conversion 60.67%
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 1.54
Altman-Z 1.93
F-Score5
WACC8.01%
ROIC/WACCN/A
Cap/Depr(3y)4495.02%
Cap/Depr(5y)15899.7%
Cap/Sales(3y)642.51%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y109.36%
EPS Next 2Y74.45%
EPS Next 3Y92.99%
EPS Next 5Y103.27%
Revenue 1Y (TTM)205.25%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%67.35%
Revenue Next Year15.78%
Revenue Next 2Y30.97%
Revenue Next 3Y51.3%
Revenue Next 5Y62.1%
EBIT growth 1Y96.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year118474%
EBIT Next 3Y1597.07%
EBIT Next 5Y591.36%
FCF growth 1Y19.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y134.82%
OCF growth 3YN/A
OCF growth 5YN/A